cy5 goat anti human igg detection ab (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
95
Structured Review
R&D Systems
cy5 goat anti human igg detection ab
Cy5 Goat Anti Human Igg Detection Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 316 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cy5+goat+anti+human+igg+detection+ab/Goat+anti-Human+IgG+(H%2BL)+Secondary+Antibody+%5BPE%2FCy5%2E5%5D/us11752213-984-11-15
Average 95 stars, based on 316 article reviews
Cy5 Goat Anti Human Igg Detection Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 316 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cy5+goat+anti+human+igg+detection+ab/Goat+anti-Human+IgG+(H%2BL)+Secondary+Antibody+%5BPE%2FCy5%2E5%5D/us11752213-984-11-15
Average 95 stars, based on 316 article reviews
cy5 goat anti human igg detection ab - by Bioz Stars,
2026-10
95/100 stars
Images
Related Articles
Comparison:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Incubation:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Derivative Assay:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Labeling:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Fluorescence:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Polymer:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Concentration Assay:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Binding Assay:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Quantitation Assay:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Adsorption:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a In Vitro:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Cell Adhesion Assay:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Expressing:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Imaging:Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).Surface Fluoroimmunoassay Against Patient APAs Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 hour, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).. Next, the surfaces were exposed to a Article Title: Surfaces having reduced non-specific binding and antigenicity Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).were tested by ELISA for IgG Ab to PEG, but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, Md.) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a Article Title: Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties Article Snippet: Informed signed consent was obtained from either the patient or from next of kin. (A) ELISA detection of APAs: Plasma samples diluted 1:21 in 1% BSA in PBS were tested by ELISA for IgG Ab to PEG essentially as described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS).described previously [ 11 , 12 , 14 ], but using Adagen® (Sigma Tau Pharmaceuticals, Gaithersburg, MD) rather than Krystexxa® as the antigen. (B) Surface fluoroimmunoassay against patient APAs: Polymer-coated surfaces were incubated with patient plasma samples diluted 1:3 in PBS for 1 h, and then washed 3 times with wash buffer (0.5% CHAPS in PBS). ... Next, the surfaces were exposed to a |